Huahai Pharmaceutical unit Huaotai to raise capital, bring in Yangtze River Delta fund

The involvement of a government-guided regional fund signals policy-backed capital is moving into biopharma subsidiaries, a pattern worth noting as such vehicles increasingly anchor early-stage life-science financing. For Huahai, bringing outside investors into a controlling subsidiary could ease balance-sheet pressure while diluting its stake, so the ownership structure after the raise is the open question. Whether this reflects a broader push by Yangtze River Delta funds into pharma platforms — or a one-off — is what to watch.